Dr. Schmidt has received consulting fees, speaking fees, and/or honoraria (less than $10,000 each) from Berlin Chemie-Menarini, Daiichi-Sankyo, Fresenius Medical Care, and Novartis.
Clinical and Health Care Use Characteristics of Patients Newly Starting Allopurinol, Febuxostat, and Colchicine for the Treatment of Gout
Version of Record online: 27 NOV 2013
Copyright © 2013 by the American College of Rheumatology
Arthritis Care & Research
Volume 65, Issue 12, pages 2008–2014, December 2013
How to Cite
Kim, S. C., Schmidt, B. M. W., Franklin, J. M., Liu, J., Solomon, D. H. and Schneeweiss, S. (2013), Clinical and Health Care Use Characteristics of Patients Newly Starting Allopurinol, Febuxostat, and Colchicine for the Treatment of Gout. Arthritis Care Res, 65: 2008–2014. doi: 10.1002/acr.22067
- Issue online: 27 NOV 2013
- Version of Record online: 27 NOV 2013
- Accepted manuscript online: 16 JUL 2013 10:02AM EST
- Manuscript Accepted: 21 JUN 2013
- Manuscript Received: 6 MAR 2013
- NIH. Grant Numbers: K23-AR059677, K24-AR055989, P60-AR047782, R21-DE018750, R01-AR056215
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.